Evaluation of a Multi-Gene Methylation Blood-Test for the Detection of Colorectal Cancer.

Q1 Medicine
Joel Petit, Georgia Carroll, Henry Williams, Peter Pockney, Rodney J Scott
{"title":"Evaluation of a Multi-Gene Methylation Blood-Test for the Detection of Colorectal Cancer.","authors":"Joel Petit,&nbsp;Georgia Carroll,&nbsp;Henry Williams,&nbsp;Peter Pockney,&nbsp;Rodney J Scott","doi":"10.3390/medsci11030060","DOIUrl":null,"url":null,"abstract":"<p><p>Circulating tumour DNA biomarkers are an expanding field in oncology research that offer great potential but are currently often limited in value by overall cost. The aim of this study was to evaluate the efficacy of a novel multi-gene methylation blood test for the identification of colorectal cancer and throughout the spectrum of colorectal disease. Participants were recruited either prior to resection for known CRC or prior to screening colonoscopy after a positive faecal immunochemical test. Blood was collected from participants prior to their procedure being performed. The plasma was separated, and multiplex MethylLight droplet digital PCR was used to analyse for the presence of four methylated genes: <i>SDC2</i>, <i>NPY</i>, <i>IKZF1</i> and <i>SEPT9</i>. A total of 537 participants underwent analysis. The <i>SDC2</i>/<i>NPY</i> genes showed a sensitivity of 33-54% and a specificity of 72-96%, whilst the <i>IKZF1</i>/<i>SEPT9</i> genes showed a sensitivity of 19-42% and a specificity of 88-96%. Combining the two tests did not significantly increase the test accuracy. The sensitivity for advanced adenoma was 2-15%. There was a significant difference in the frequency of detectable methylation between the participants with CRC and those without CRC. However, neither the sensitivity nor the specificity was superior to current diagnostic screening tests.</p>","PeriodicalId":74152,"journal":{"name":"Medical sciences (Basel, Switzerland)","volume":"11 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534804/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical sciences (Basel, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/medsci11030060","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Circulating tumour DNA biomarkers are an expanding field in oncology research that offer great potential but are currently often limited in value by overall cost. The aim of this study was to evaluate the efficacy of a novel multi-gene methylation blood test for the identification of colorectal cancer and throughout the spectrum of colorectal disease. Participants were recruited either prior to resection for known CRC or prior to screening colonoscopy after a positive faecal immunochemical test. Blood was collected from participants prior to their procedure being performed. The plasma was separated, and multiplex MethylLight droplet digital PCR was used to analyse for the presence of four methylated genes: SDC2, NPY, IKZF1 and SEPT9. A total of 537 participants underwent analysis. The SDC2/NPY genes showed a sensitivity of 33-54% and a specificity of 72-96%, whilst the IKZF1/SEPT9 genes showed a sensitivity of 19-42% and a specificity of 88-96%. Combining the two tests did not significantly increase the test accuracy. The sensitivity for advanced adenoma was 2-15%. There was a significant difference in the frequency of detectable methylation between the participants with CRC and those without CRC. However, neither the sensitivity nor the specificity was superior to current diagnostic screening tests.

Abstract Image

多基因甲基化血液检测法检测大肠癌癌症的评价。
循环肿瘤DNA生物标志物是肿瘤学研究中一个不断扩大的领域,具有巨大的潜力,但目前其价值往往受到整体成本的限制。本研究的目的是评估一种新的多基因甲基化血液检测在结直肠癌癌症和整个结直肠癌谱系中的有效性。参与者在已知CRC切除前或在粪便免疫化学测试呈阳性后进行结肠镜检查筛查前被招募。在参与者进行手术之前,从他们身上采集血液。分离血浆,并使用多重MethylLight液滴数字PCR来分析四个甲基化基因的存在:SDC2、NPY、IKZF1和SEPT9。共有537名参与者接受了分析。SDC2/NPY基因显示出33-54%的敏感性和72-96%的特异性,而IKZF1/SEPT9基因显示了19-42%的敏感性和88-96%的特异性。将这两种测试结合起来并没有显著提高测试的准确性。对晚期腺瘤的敏感性为2~15%。CRC患者和非CRC患者的可检测甲基化频率存在显著差异。然而,无论是敏感性还是特异性都不优于目前的诊断筛查测试。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
9.00
自引率
0.00%
发文量
0
审稿时长
6 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信